Abbott has unveiled its next-generation continuous glucose monitoring (CGM) device, the FreeStyle Libre 2 Plus, in India, marking a significant step forward in diabetes management. This new device provides real-time glucose readings every minute and can be worn for up to 15 days, offering users the convenience of tracking their blood sugar levels directly on their smartphones without the need for manual scans.

The FreeStyle Libre 2 Plus is an upgrade to Abbott’s previous CGM offerings, already trusted by over 7 million people in more than 60 countries. This device allows for seamless integration with Abbott’s digital health ecosystem, including LibreView and LibreLinkUp, enabling both caregivers and healthcare professionals to remotely monitor patients’ glucose levels.

India, with its vast diabetes population of over 101 million people, stands to benefit greatly from this innovation. The new system eliminates the need for traditional fingerstick testing, empowering patients to manage their condition more effectively. Clinical studies have shown that the FreeStyle Libre technology can significantly reduce episodes of hypoglycemia, lower HbA1c levels, and reduce hospital visits, making it a promising tool in diabetes care.

The device is now available across India for both adults and children aged two and above, including pregnant women with gestational diabetes. Abbott’s launch comes as the demand for accessible, real-time diabetes management solutions grows, particularly with the rise of CGM adoption and the integration of digital health technologies.

Image Source: Google | Image Credit: Respective Owner